0001555667-16-000060.txt : 20160309
0001555667-16-000060.hdr.sgml : 20160309
20160309205053
ACCESSION NUMBER: 0001555667-16-000060
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160308
FILED AS OF DATE: 20160309
DATE AS OF CHANGE: 20160309
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLAZYME INC
CENTRAL INDEX KEY: 0001311230
STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860]
IRS NUMBER: 331077078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 225 GATEWAY BLVD.
CITY: S. SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-780-4777
MAIL ADDRESS:
STREET 1: 225 GATEWAY BLVD.
CITY: S. SAN FRANCISCO
STATE: CA
ZIP: 94080
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quinlan Paul T
CENTRAL INDEX KEY: 0001333277
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35189
FILM NUMBER: 161495962
BUSINESS ADDRESS:
BUSINESS PHONE: (650) 780-4777
MAIL ADDRESS:
STREET 1: SOLAZYME, INC.
STREET 2: 225 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2016-03-08
0001311230
SOLAZYME INC
SZYM
0001333277
Quinlan Paul T
SOLAZYME, INC.
225 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
General Counsel
Common Stock
2016-03-08
4
S
0
1562
1.6646
D
75193
D
Common Stock
2016-03-08
4
A
0
62500
0
A
137693
D
Employee Stock Option (right to buy)
1.66
2016-03-08
4
A
0
350000
0
A
2026-03-07
Common Stock
350000
350000
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was designed to cover tax withholding obligations in connection with the concurrent vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.69, inclusive. The reporting person undertakes to provide to Solazyme, Inc., any security holder of Solazyme, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The grant shall vest as to 1/4 of the shares on March 9, 2017 and thereafter shall vest as to 1/8 of the shares on each of September 14, 2017, March 8, 2018, September 14, 2018, March 1, 2019, September 11, 2019 and March 11, 2020.
The option shall vest as to 1/48 of the underlying shares monthly beginning on February 1, 2016.
/s/ Rob Maynes, as attorney-in-fact
2016-03-09